Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma

Medicine and Dentistry

• Adverse Event 25%
• Biological Therapy 50%
• Ciclesonide 50%
• Cyclosporine 25%
• Drug Dose Reduction 100%
• Inhalational Drug Administration 25%
• Maintenance Therapy 100%
• Masitinib 25%
• Mepolizumab 25%
• Meta-Analysis 25%
• Methotrexate 25%
• Mometasone Furoate 25%
• Omalizumab 25%
• Severe Asthma 100%
• Systematic Review 50%

Keyphrases

• Biologic Therapy 14%
• Ciclesonide 14%
• Corticosteroid Dose 71%
• Corticosteroid-sparing 14%
• Cyclosporine 7%
• Dose Reduction 28%
• Inhaled Corticosteroids 7%
• Low Potential 7%
• Maintenance Therapy 100%
• Management Strategy 7%
• Masitinib 7%
• Mepolizumab 7%
• Meta-analysis 7%
• Methotrexate 7%
• Mometasone Furoate 7%
• Non-biologic 7%
• Omalizumab 7%
• Oral Corticosteroids 100%
• Reporting Item 7%
• Serious Adverse Effects 7%
• Severe Asthma 100%
• Steroid-sparing 7%
• Systematic Literature Review 7%
• Systematic Meta-analysis 7%
• Systemic Effects 7%
• Systemic Steroids 7%
• Web-based 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 25%
• Asthma 100%
• Biological Product 25%
• Ciclesonide 50%
• Ciclosporin 25%
• Masitinib 25%
• Mepolizumab 25%
• Methotrexate 25%
• Mometasone Furoate 25%
• Omalizumab 25%